Compare CURV & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CURV | OLMA |
|---|---|---|
| Founded | 2001 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 219.9M | 1.1B |
| IPO Year | 2021 | 2020 |
| Metric | CURV | OLMA |
|---|---|---|
| Price | $2.09 | $10.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $1.59 | ★ $44.89 |
| AVG Volume (30 Days) | 235.6K | ★ 1.0M |
| Earning Date | 06-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,000,092,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.15 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.94 | $5.36 |
| 52 Week High | $2.86 | $36.26 |
| Indicator | CURV | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 43.38 | 44.57 |
| Support Level | $1.99 | $9.70 |
| Resistance Level | $2.18 | $12.37 |
| Average True Range (ATR) | 0.13 | 0.52 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 21.88 | 40.24 |
Torrid Holdings Inc is a direct-to-consumer brand in North America dedicated to offering a diverse assortment of stylish apparel, intimates, and accessories skillfully designed for curvy women. Its extensive collection features high-quality merchandise, including tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of its e-Commerce platform and stores.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.